Results 121 to 130 of about 259,384 (291)
Bayesian Estimation Improves Prediction of Outcomes After Epilepsy Surgery
ABSTRACT We estimated the statistical power of studies predicting seizure freedom after epilepsy surgery. We extracted data from a Cochrane meta‐analysis. The median power across all studies was 14%. Studies with a median sample size or less (n ≤ 56) and a statistically significant result exaggerated the true effect size by a factor of 5.4, while the ...
Adam S. Dickey +4 more
wiley +1 more source
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu +10 more
wiley +1 more source
Additional file 1: of GSTM3, but not IZUMO1, is a cryotolerance marker of boar sperm
Marc Llavanera +7 more
openalex +1 more source
ABSTRACT Objective To delineate specific in vivo white matter pathology in neuronal intranuclear inclusion disease (NIID) using diffusion spectrum imaging (DSI) and define its clinical relevance. Methods DSI was performed on 42 NIID patients and 38 matched controls.
Kaiyan Jiang +10 more
wiley +1 more source
Supplementary File 2A presents the results of the enrichment analysis of Gene Ontology (GO) terms in the comparison of subcutaneous adipose tissue proteins from patients with severe obesity before metabolic bariatric surgery and controls without obesity.
openaire +1 more source
We report the national burden of dermatopolymyositis mortality over the past quarter century using the US national vital statistics data. Age‐standardized mortality rates for dermatopolymyositis decreased at an annual rate of 3.8% each year, which was higher than the annual percent decrease for deaths from all other causes.
Elizabeth Matz, Ram R. Singh
wiley +1 more source
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang +4 more
wiley +1 more source

